New PET scan tracer for detecting cancer using EphA2
Part of Cancer clinical trials.
This study tests a new radioactive tracer (a type of dye) called 68Ga-DOTA-EphA2 that helps PET scanners find cancer cells. Researchers want to see if this tracer can better identify tumors in patients who may have cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old
- You have suspected or confirmed cancer with at least one tumor large enough to be seen on imaging (CT, MRI, or ultrasound)
- You are in good enough overall health to have a PET/CT scan (ECOG score of 0–2, meaning you can do most daily activities)
- Your liver, kidneys, heart, and lungs work well enough for safe PET/CT imaging
- You have not been in another drug or radioactive imaging study in the past 4 weeks
- You can hold still during a PET/CT scan and understand the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This study tests a new imaging technique using a special tracer (68Ga-DOTA-BLP) that may help spot cancer more accurately. It is for people with confirmed cancer who have suspicious lymph nodes or possible spread, and who have not yet started cancer treatment.
This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
This study tests a new type of imaging agent (called a tracer) that helps PET scans see tumors more clearly. It may help doctors find and monitor cancer better.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.